Results 171 to 180 of about 16,195 (312)

The Optimisation of Carrier Selection in Dry Powder Inhaler Formulation and the Role of Surface Energetics. [PDF]

Biomedicines, 2022
Abiona O, Wyatt D, Koner J, Mohammed A.
europepmc   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Future of Carrier-Free Dry Powder Inhaler Formulations [PDF]

Pharmaceutical Sciences
Ali Nokhodchi, Taravat Ghafourian
doaj   +1 more source

Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older

International Journal of COPD, 2014
Yuko Komase,1 Akimoto Asako,2 Akihiro Kobayashi,3 Raj Sharma4 1Department of Respiratory Internal Medicine, St Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan; 2MA Respiratory Department, Development and ...
Komase Y, Asako A, Kobayashi A, Sharma R
doaj  

Advancement of a high-dose infant air-jet dry powder inhaler (DPI) with passive cyclic loading: Performance tuning for different formulations. [PDF]

Int J Pharm, 2023
Howe C, Momin MAM, Aladwani G, Strickler S, Hindle M, Longest W.   +5 more
europepmc   +1 more source

Asthma patient satisfaction with different dry powder inhalers [PDF]

, 2019
Antonio Valero, Paula Ribó, Luís Máiz, Esther Barbero, Myriam Calle Rubio, Carlos Campo, Paula Rytilä, Jordi Giner, Vicente Plaza   +8 more
openalex   +1 more source

Decarbonising Respiratory Care: The Impact of a Low‐Carbon Salbutamol Pressurised Metered‐Dose Inhalers

Allergy, EarlyView.
Healthcare systems contribute up to 5% of global GHG emissions, with inhalers contributing a proportion of these. The carbon footprint of current salbutamol inhalers (pMDI with HFA‐134a propellant and DPI) and a planned salbutamol pMDI with low‐GWP propellant HFA‐152a was quantified across seven countries.
James King, Ashley Woodcock, Antonio Anzueto, Alexander J. K. Wilkinson, Christer Janson, Richard Henderson, Sourabh Fulmali, Maximilian Plank   +7 more
wiley   +1 more source

78 Comparison of pierced versus broken capsules on delivered fine particle dose for the colistimethate dry powder inhaler

, 2014
May Ng, A. Kassamali, C. Scott
openalex   +1 more source

Addressing the Global Challenges of COPD and Asthma: A Shared Vision From the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA)

Respirology, EarlyView.
David M. G. Halpin, Refiloe Masekela, Claus F. Vogelmeier, Obianuju B. Ozoh, Alvaro A. Cruz, Helen K. Reddel, Arzu Yorgancıoğlu, Alvar Agusti, on behalf of the Boards of Directors of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Global Initiative for Asthma (GINA), Alvar Agusti, Bartolome R. Celli, Gerard Criner, David Halpin, Maria Montes de Oca, Obianuju B. Ozoh, Sundeep Salvi, Claus Vogelmeier, Jinping Zheng, Arzu Yorgancioglu, Keith Allan, Guy Brusselle, Muhwa Jeremiah Chakaya, Alvaro A. Cruz, Hiromasa Inoue, Jerry A. Krishnan, Mark L. Levy, Helen K. Reddel   +26 more
wiley   +1 more source

Allyl isothiocyanate dry powder inhaler based on cyclodextrin-metal organic frameworks for pulmonary delivery. [PDF]

iScience, 2023
Sun N, Zhang M, Zhu W, Song P, Dai T, Huang P, Han Z, Wang D.   +7 more
europepmc   +1 more source